Prascend® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Prascend®

Active ingredient

Pergolide mesylate

Application type

NADA

Sponsor

Boehringer lngelheim Animal Health USA, Inc.

Applications on record

1

First published

June 1, 2016

Adverse event reports

Source: openFDA VeDDRA

1,351

Reports mentioning this ingredient

December 29, 2011 – March 6, 2026

431

Classified serious

per reporter assessment

125

Lack of expected efficacy

resistance signal

54

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “PERGOLIDE MESYLATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Anorexia	223
Lethargy (see also Central nervous system depression in 'Neurological')	122
Diarrhoea	115
Behavioural disorder NOS	88
Lack of efficacy - NOS	72
Weight loss	71
Inappetence	66
Colic	63
Other abnormal test result NOS	59
Death by euthanasia	56
Accidental exposure	54
Depression	53
Lameness	50
Laminitis	49
INEFFECTIVE, CUSHINGS	48
Decreased appetite	45
Ataxia	42
Vomiting	40
Aggression	37
Death	31

Species affected

Source: openFDA VeDDRA

Horse 1,165 Dog 82 Human 22 Donkey 11 Cat 5 Mule 3 Cattle 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient